{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T04:32:27Z","timestamp":1776918747065,"version":"3.51.2"},"reference-count":75,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1124\/jpet.117.242503","type":"journal-article","created":{"date-parts":[[2017,9,20]],"date-time":"2017-09-20T00:50:23Z","timestamp":1505868623000},"page":"336-347","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":85,"title":["Discovery and Preclinical Characterization of GSK1278863 (Daprodustat), a Small Molecule Hypoxia Inducible Factor\u2013Prolyl Hydroxylase Inhibitor for Anemia"],"prefix":"10.1016","volume":"363","author":[{"given":"Jennifer L.","family":"Ariazi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin J.","family":"Duffy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David F.","family":"Adams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Duke M.","family":"Fitch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lusong","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa","family":"Pappalardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mangatt","family":"Biju","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erin Hugger","family":"DiFilippo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tony","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Wiggall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Connie","family":"Erickson-Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.117.242503_bib1","doi-asserted-by":"crossref","first-page":"3680","DOI":"10.1021\/jm400193d","article-title":"Structural basis for inhibition of the fat mass and obesity associated protein (FTO)","volume":"56","author":"Aik","year":"2013","journal-title":"J Med Chem"},{"key":"10.1124\/jpet.117.242503_bib2","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1159\/000454818","article-title":"Effects of daprodustat, a novel hypoxia-inducible factor prolyl hydroxylase inhibitor on anemia management in Japanese hemodialysis subjects","volume":"45","author":"Akizawa","year":"2017","journal-title":"Am J Nephrol"},{"key":"10.1124\/jpet.117.242503_bib3","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1177\/0192623311416259","article-title":"Induction of heart valve lesions by small-molecule ALK5 inhibitors","volume":"39","author":"Anderton","year":"2011","journal-title":"Toxicol Pathol"},{"key":"10.1124\/jpet.117.242503_bib4","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1177\/0192623313486319","article-title":"Dose-related differences in the pharmacodynamic and toxicologic response to a novel hyperglycosylated analog of recombinant human erythropoietin in Sprague-Dawley rats with similarly high hematocrit","volume":"42","author":"Andrews","year":"2014","journal-title":"Toxicol Pathol"},{"key":"10.1124\/jpet.117.242503_bib5","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1177\/0192623313486317","article-title":"High hematocrit resulting from administration of erythropoiesis-stimulating agents is not fully predictive of mortality or toxicities in preclinical species","volume":"42","author":"Andrews","year":"2014","journal-title":"Toxicol Pathol"},{"key":"10.1124\/jpet.117.242503_bib6","doi-asserted-by":"crossref","first-page":"38458","DOI":"10.1074\/jbc.M406026200","article-title":"Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible factor","volume":"279","author":"Appelhoff","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1124\/jpet.117.242503_bib7","doi-asserted-by":"crossref","DOI":"10.1186\/gb-2001-2-3-research0007","article-title":"The DNA-repair protein AlkB, EGL-9, and leprecan define new families of 2-oxoglutarate- and iron-dependent dioxygenases","volume":"2","author":"Aravind","year":"2001","journal-title":"Genome Biol"},{"key":"10.1124\/jpet.117.242503_bib8","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.exer.2006.01.016","article-title":"Oxygen-dependent diseases in the retina: role of hypoxia-inducible factors","volume":"83","author":"Arjamaa","year":"2006","journal-title":"Exp Eye Res"},{"key":"10.1124\/jpet.117.242503_bib9","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/FJC.0b013e3181e2bfef","article-title":"Chronic inhibition of hypoxia-inducible factor prolyl 4-hydroxylase improves ventricular performance, remodeling, and vascularity after myocardial infarction in the rat","volume":"56","author":"Bao","year":"2010","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1124\/jpet.117.242503_bib10","doi-asserted-by":"crossref","first-page":"4082","DOI":"10.1093\/emboj\/cdg392","article-title":"HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1\u03b1 in normoxia","volume":"22","author":"Berra","year":"2003","journal-title":"EMBO J"},{"key":"10.1124\/jpet.117.242503_bib11","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1161\/CIRCRESAHA.117.305109","article-title":"HIF hydroxylase pathways in cardiovascular physiology and medicine","volume":"117","author":"Bishop","year":"2015","journal-title":"Circ Res"},{"key":"10.1124\/jpet.117.242503_bib12","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1053\/j.ajkd.2015.11.021","article-title":"A novel hypoxia-inducible factor-prolyl hydroxylase inhibitor (GSK1278863) for anemia in CKD: a 28-day, phase 2A randomized trial","volume":"67","author":"Brigandi","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"10.1124\/jpet.117.242503_bib13","unstructured":"Chai D, Colon M, Duffy KJ, Fitch DM, Tedesco R and Zimmerman M (2007) inventors, Smithkline Beecham Corporation, assignee. Prolyl hydroxylase antagonists. WIPO patent WO 2007038571 A2. 2005 Sep 26."},{"key":"10.1124\/jpet.117.242503_bib14","doi-asserted-by":"crossref","first-page":"20661","DOI":"10.1074\/jbc.M116.749291","article-title":"Tuning the transcriptional response to hypoxia by inhibiting hypoxia-inducible factor (HIF) prolyl and asparaginyl hydroxylases","volume":"291","author":"Chan","year":"2016","journal-title":"J Biol Chem"},{"key":"10.1124\/jpet.117.242503_bib15","doi-asserted-by":"crossref","first-page":"4768","DOI":"10.1039\/b809099h","article-title":"Auto-hydroxylation of FIH-1: an Fe(ii), \u03b1-ketoglutarate-dependent human hypoxia sensor","volume":"39","author":"Chen","year":"2008","journal-title":"Chem Commun (Camb)"},{"key":"10.1124\/jpet.117.242503_bib16","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/0006-2952(73)90196-2","article-title":"Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction","volume":"22","author":"Cheng","year":"1973","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/jpet.117.242503_bib17","doi-asserted-by":"crossref","first-page":"25733","DOI":"10.1074\/jbc.M002740200","article-title":"Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein","volume":"275","author":"Cockman","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1124\/jpet.117.242503_bib18","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1056\/NEJM199708283370901","article-title":"Valvular heart disease associated with fenfluramine-phentermine","volume":"337","author":"Connolly","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.117.242503_bib19","first-page":"1","article-title":"Evaluation of enzyme inhibitors in drug discovery. A guide for medicinal chemists and pharmacologists","volume":"46","author":"Copeland","year":"2005","journal-title":"Methods Biochem Anal"},{"key":"10.1124\/jpet.117.242503_bib20","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1021\/jm00092a016","article-title":"Novel inhibitors of prolyl 4-hydroxylase. 3. Inhibition by the substrate analogue N-oxaloglycine and its derivatives","volume":"35","author":"Cunliffe","year":"1992","journal-title":"J Med Chem"},{"key":"10.1124\/jpet.117.242503_bib21","unstructured":"Duffy KJ, Fitch DM, Jin J, Liu R, Shaw A, N, and Wiggall KJ (2007) inventors, Smithkline Beecham Corporation, assignee. Prolyl hydroxylase inhibitors. WIPO patent WO 2007150011 A8. 2006 Jun 23."},{"key":"10.1124\/jpet.117.242503_bib22","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0092-8674(01)00507-4","article-title":"C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation","volume":"107","author":"Epstein","year":"2001","journal-title":"Cell"},{"key":"10.1124\/jpet.117.242503_bib23","first-page":"178","article-title":"AlkB-mediated oxidative demethylation reverses DNA damage","volume":"419","author":"Falnes","year":"2002","journal-title":"Escherichia coli Nature"},{"key":"10.1124\/jpet.117.242503_bib24","doi-asserted-by":"crossref","first-page":"135","DOI":"10.5966\/sctm.2013-0134","article-title":"Targeting the hypoxia-sensing pathway in clinical hematology","volume":"3","author":"Forristal","year":"2014","journal-title":"Stem Cells Transl Med"},{"key":"10.1124\/jpet.117.242503_bib25","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.exer.2005.12.007","article-title":"Transforming growth factor \u03b22-induced myofibroblastic differentiation of human retinal pigment epithelial cells: regulation by extracellular matrix proteins and hepatocyte growth factor","volume":"83","author":"Gamulescu","year":"2006","journal-title":"Exp Eye Res"},{"key":"10.1124\/jpet.117.242503_bib26","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1001\/jama.1989.03430040095032","article-title":"Association of mitral valve prolapse and systemic abnormalities of connective tissue. A phenotypic continuum","volume":"262","author":"Glesby","year":"1989","journal-title":"JAMA"},{"key":"10.1124\/jpet.117.242503_bib27","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1172\/JCI117155","article-title":"A patient with Ehlers-Danlos syndrome type VI is a compound heterozygote for mutations in the lysyl hydroxylase gene","volume":"93","author":"Ha","year":"1994","journal-title":"J Clin Invest"},{"key":"10.1124\/jpet.117.242503_bib28","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00109-008-0400-9","article-title":"Molecular mechanisms underlying the onset of degenerative aortic valve disease","volume":"87","author":"Hakuno","year":"2009","journal-title":"J Mol Med (Berl)"},{"key":"10.1124\/jpet.117.242503_bib29","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1080\/10409230490440541","article-title":"FeII\/alpha-ketoglutarate-dependent hydroxylases and related enzymes","volume":"39","author":"Hausinger","year":"2004","journal-title":"Crit Rev Biochem Mol Biol"},{"key":"10.1124\/jpet.117.242503_bib30","doi-asserted-by":"crossref","first-page":"26351","DOI":"10.1074\/jbc.C200273200","article-title":"Hypoxia-inducible factor (HIF) asparagine hydroxylase is identical to factor inhibiting HIF (FIH) and is related to the cupin structural family","volume":"277","author":"Hewitson","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1124\/jpet.117.242503_bib31","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1161\/01.RES.0000224114.65109.4e","article-title":"Extracellular matrix remodeling and organization in developing and diseased aortic valves","volume":"98","author":"Hinton","year":"2006","journal-title":"Circ Res"},{"key":"10.1124\/jpet.117.242503_bib32","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1126\/science.1852076","article-title":"Cloning of a factor required for activity of the Ah (dioxin) receptor","volume":"252","author":"Hoffman","year":"1991","journal-title":"Science"},{"key":"10.1124\/jpet.117.242503_bib33","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1681\/ASN.2014111139","article-title":"Four-week studies of oral hypoxia-inducible factor-prolyl hydroxylase inhibitor GSK1278863 for treatment of anemia","volume":"27","author":"Holdstock","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"10.1124\/jpet.117.242503_bib34","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.immuni.2015.03.005","article-title":"The methylcytosine dioxygenase Tet2 promotes DNA demethylation and activation of cytokine gene expression in T cells","volume":"42","author":"Ichiyama","year":"2015","journal-title":"Immunity"},{"key":"10.1124\/jpet.117.242503_bib35","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1126\/science.1059817","article-title":"HIF\u03b1 targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing","volume":"292","author":"Ivan","year":"2001","journal-title":"Science"},{"key":"10.1124\/jpet.117.242503_bib36","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1126\/science.1059796","article-title":"Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation","volume":"292","author":"Jaakkola","year":"2001","journal-title":"Science"},{"key":"10.1124\/jpet.117.242503_bib37","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1161\/01.CIR.64.1.121","article-title":"Mitral valve prolapse: a consistent manifestation of type IV Ehlers-Danlos syndrome. The pathogenetic role of the abnormal production of type III collagen","volume":"64","author":"Jaffe","year":"1981","journal-title":"Circulation"},{"key":"10.1124\/jpet.117.242503_bib38","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1021\/acschembio.6b00080","article-title":"Interrogating the druggability of the 2-oxoglutarate-dependent dioxygenase target class by chemical proteomics","volume":"11","author":"Joberty","year":"2016","journal-title":"ACS Chem Biol"},{"key":"10.1124\/jpet.117.242503_bib39","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2217\/epi.13.79","article-title":"The roles of Jumonji-type oxygenases in human disease","volume":"6","author":"Johansson","year":"2014","journal-title":"Epigenomics"},{"key":"10.1124\/jpet.117.242503_bib40","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/cpdd.83","article-title":"Effect of food and gemfibrozil on the pharmacokinetics of the novel prolyl hydroxylase inhibitor GSK1278863","volume":"3","author":"Johnson","year":"2014","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1124\/jpet.117.242503_bib41","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.pep.2004.09.008","article-title":"Production of human prolyl 4-hydroxylase in Escherichia coli","volume":"38","author":"Kersteen","year":"2004","journal-title":"Protein Expr Purif"},{"key":"10.1124\/jpet.117.242503_bib42","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1101\/gad.991402","article-title":"FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor","volume":"16","author":"Lando","year":"2002","journal-title":"Genes Dev"},{"key":"10.1124\/jpet.117.242503_bib43","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1139\/o02-115","article-title":"Mammalian EGLN genes have distinct patterns of mRNA expression and regulation","volume":"80","author":"Lieb","year":"2002","journal-title":"Biochem Cell Biol"},{"key":"10.1124\/jpet.117.242503_bib44","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.ydbio.2006.03.027","article-title":"Hearts and bones: shared regulatory mechanisms in heart valve, cartilage, tendon, and bone development","volume":"294","author":"Lincoln","year":"2006","journal-title":"Dev Biol"},{"key":"10.1124\/jpet.117.242503_bib45","doi-asserted-by":"crossref","first-page":"4635","DOI":"10.1172\/JCI63924","article-title":"Hypoxia-inducible factor regulates hepcidin via erythropoietin-induced erythropoiesis","volume":"122","author":"Liu","year":"2012","journal-title":"J Clin Invest"},{"key":"10.1124\/jpet.117.242503_bib46","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s10059-010-0067-2","article-title":"HIF-1 and HIF-2 transcription factors\u2014similar but not identical","volume":"29","author":"Loboda","year":"2010","journal-title":"Mol Cells"},{"key":"10.1124\/jpet.117.242503_bib47","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.vph.2012.02.006","article-title":"HIF-1 versus HIF-2\u2014is one more important than the other?","volume":"56","author":"Loboda","year":"2012","journal-title":"Vascul Pharmacol"},{"key":"10.1124\/jpet.117.242503_bib48","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1101\/gad.924501","article-title":"FIH-1: a novel protein that interacts with HIF-1\u03b1 and VHL to mediate repression of HIF-1 transcriptional activity","volume":"15","author":"Mahon","year":"2001","journal-title":"Genes Dev"},{"key":"10.1124\/jpet.117.242503_bib49","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/35107085","article-title":"Inhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression","volume":"414","author":"Makino","year":"2001","journal-title":"Nature"},{"key":"10.1124\/jpet.117.242503_bib50","doi-asserted-by":"crossref","first-page":"e112","DOI":"10.3324\/haematol.2013.102319","article-title":"Investigating the real role of HIF-1 and HIF-2 in iron recycling by macrophages","volume":"99","author":"Mathieu","year":"2014","journal-title":"Haematologica"},{"key":"10.1124\/jpet.117.242503_bib51","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/20459","article-title":"The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis","volume":"399","author":"Maxwell","year":"1999","journal-title":"Nature"},{"key":"10.1124\/jpet.117.242503_bib52","doi-asserted-by":"crossref","first-page":"9814","DOI":"10.1073\/pnas.0601283103","article-title":"Cellular oxygen sensing: crystal structure of hypoxia-inducible factor prolyl hydroxylase (PHD2)","volume":"103","author":"McDonough","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/jpet.117.242503_bib53","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.1182\/blood-2007-10-117812","article-title":"Somatic inactivation of the PHD2 prolyl hydroxylase causes polycythemia and congestive heart failure","volume":"111","author":"Minamishima","year":"2008","journal-title":"Blood"},{"key":"10.1124\/jpet.117.242503_bib54","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1016\/S0960-894X(03)00539-0","article-title":"2-Oxoglutarate analogue inhibitors of HIF prolyl hydroxylase","volume":"13","author":"Mole","year":"2003","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1124\/jpet.117.242503_bib55","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3109\/07853890109002055","article-title":"Collagens and collagen-related diseases","volume":"33","author":"Myllyharju","year":"2001","journal-title":"Ann Med"},{"key":"10.1124\/jpet.117.242503_bib56","doi-asserted-by":"crossref","first-page":"11165","DOI":"10.1021\/bi801624f","article-title":"Biochemical characterization of human prolyl hydroxylase domain protein 2 variants associated with erythrocytosis","volume":"47","author":"Pappalardi","year":"2008","journal-title":"Biochemistry"},{"key":"10.1124\/jpet.117.242503_bib57","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1042\/BJ20101201","article-title":"Biochemical characterization of human HIF hydroxylases using HIF protein substrates that contain all three hydroxylation sites","volume":"436","author":"Pappalardi","year":"2011","journal-title":"Biochem J"},{"key":"10.1124\/jpet.117.242503_bib58","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1073\/pnas.0508423103","article-title":"A family with erythrocytosis establishes a role for prolyl hydroxylase domain protein 2 in oxygen homeostasis","volume":"103","author":"Percy","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/jpet.117.242503_bib59","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.ejheart.2005.10.009","article-title":"Stabilization of hypoxia inducible factor rather than modulation of collagen metabolism improves cardiac function after acute myocardial infarction in rats","volume":"8","author":"Philipp","year":"2006","journal-title":"Eur J Heart Fail"},{"key":"10.1124\/jpet.117.242503_bib60","doi-asserted-by":"crossref","first-page":"10553","DOI":"10.1073\/pnas.88.23.10553","article-title":"Functional analysis of an oxygen-regulated transcriptional enhancer lying 3\u2032 to the mouse erythropoietin gene","volume":"88","author":"Pugh","year":"1991","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/jpet.117.242503_bib61","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1172\/JCI31750","article-title":"HIF-1 and HIF-2: working alone or together in hypoxia?","volume":"117","author":"Ratcliffe","year":"2007","journal-title":"J Clin Invest"},{"key":"10.1124\/jpet.117.242503_bib62","doi-asserted-by":"crossref","first-page":"e207","DOI":"10.1182\/blood-2010-10-314427","article-title":"High-resolution genome-wide mapping of HIF-binding sites by ChIP-seq","volume":"117","author":"Sch\u00f6del","year":"2011","journal-title":"Blood"},{"key":"10.1124\/jpet.117.242503_bib63","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.cell.2012.01.021","article-title":"Hypoxia-inducible factors in physiology and medicine","volume":"148","author":"Semenza","year":"2012","journal-title":"Cell"},{"key":"10.1124\/jpet.117.242503_bib64","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/0-306-46825-5_12","article-title":"Hypoxia, HIF-1, and the pathophysiology of common human diseases","volume":"475","author":"Semenza","year":"2000","journal-title":"Adv Exp Med Biol"},{"key":"10.1124\/jpet.117.242503_bib65","doi-asserted-by":"crossref","first-page":"5680","DOI":"10.1073\/pnas.88.13.5680","article-title":"Hypoxia-inducible nuclear factors bind to an enhancer element located 3\u2032 to the human erythropoietin gene","volume":"88","author":"Semenza","year":"1991","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/jpet.117.242503_bib66","first-page":"5447","article-title":"A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation","volume":"12","author":"Semenza","year":"1992","journal-title":"Mol Cell Biol"},{"key":"10.1124\/jpet.117.242503_bib67","unstructured":"Shaw AN, Duffy KJ, Miller WH, Myers AK and Zimmerman M (2008) inventors, Smithkline Beecham Corporation, assignee. N-substituted glycine derivatives: prolyl hydroxylase inhibitors. WIPO patent WO2008089052 A2. 2007 Jan 12."},{"key":"10.1124\/jpet.117.242503_bib75","first-page":"161","article-title":"Erythropoiesis stimulating agents: approaches to modulate activity","volume":"7","author":"Sinclair","year":"2013","journal-title":"Biologics"},{"key":"10.1124\/jpet.117.242503_bib68","doi-asserted-by":"crossref","first-page":"3229","DOI":"10.1182\/blood-2007-09-114561","article-title":"Regulation of adult erythropoiesis by prolyl hydroxylase domain proteins","volume":"111","author":"Takeda","year":"2008","journal-title":"Blood"},{"key":"10.1124\/jpet.117.242503_bib69","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1101\/gad.11.1.72","article-title":"Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells","volume":"11","author":"Tian","year":"1997","journal-title":"Genes Dev"},{"key":"10.1124\/jpet.117.242503_bib70","doi-asserted-by":"crossref","first-page":"5510","DOI":"10.1073\/pnas.92.12.5510","article-title":"Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension","volume":"92","author":"Wang","year":"1995","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/jpet.117.242503_bib71","doi-asserted-by":"crossref","first-page":"E841","DOI":"10.1073\/pnas.1202081109","article-title":"Endothelial expression of hypoxia-inducible factor 1 protects the murine heart and aorta from pressure overload by suppression of TGF-\u03b2 signaling","volume":"109","author":"Wei","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/jpet.117.242503_bib72","doi-asserted-by":"crossref","first-page":"S271","DOI":"10.1513\/AnnalsATS.201403-108AW","article-title":"The regulation of pulmonary inflammation by the hypoxia-inducible factor-hydroxylase oxygen-sensing pathway","volume":"11","author":"Whyte","year":"2014","journal-title":"Ann Am Thorac Soc"},{"key":"10.1124\/jpet.117.242503_bib73","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1749-6632.2009.05027.x","article-title":"Role of hypoxia-inducible factors in epigenetic regulation via histone demethylases","volume":"1177","author":"Yang","year":"2009","journal-title":"Ann N Y Acad Sci"},{"key":"10.1124\/jpet.117.242503_bib74","doi-asserted-by":"crossref","first-page":"25703","DOI":"10.1074\/jbc.M602329200","article-title":"Hypoxia-inducible factor-1 deficiency results in dysregulated erythropoiesis signaling and iron homeostasis in mouse development","volume":"281","author":"Yoon","year":"2006","journal-title":"J Biol Chem"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524271305?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524271305?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.117.242503","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T20:07:46Z","timestamp":1739995666000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524271305"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":75,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["S0022356524271305"],"URL":"https:\/\/doi.org\/10.1124\/jpet.117.242503","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery and Preclinical Characterization of GSK1278863 (Daprodustat), a Small Molecule Hypoxia Inducible Factor\u2013Prolyl Hydroxylase Inhibitor for Anemia","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.117.242503","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}